Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» FDA gives Novo Nordisk top grades for its diabetes drug semaglutide, but retinopathy remains key
FDA gives Novo Nordisk top grades for its diabetes drug semaglutide, but retinopathy remains key
FDA gives Novo Nordisk top grades for its diabetes drug semaglutide, but retinopathy remains key
Submitted by
admin
on October 16, 2017 - 9:42am
Source:
Endpoints
News Tags:
FDA
Novo Nordisk
diabetes
semaglutide
diabetic retinopathy
Headline:
FDA gives Novo Nordisk top grades for its diabetes drug semaglutide, but retinopathy remains key
Do Not Allow Advertisers to Use My Personal information
